Compare BSRR & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSRR | GYRE |
|---|---|---|
| Founded | 1977 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.7M | 573.4M |
| IPO Year | 2001 | 2004 |
| Metric | BSRR | GYRE |
|---|---|---|
| Price | $38.54 | $6.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $37.00 | $17.00 |
| AVG Volume (30 Days) | 53.7K | ★ 85.3K |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | ★ 10.28 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | N/A | ★ $275,000.00 |
| Revenue This Year | $11.74 | $19.88 |
| Revenue Next Year | $3.63 | N/A |
| P/E Ratio | $39.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.49 | $5.44 |
| 52 Week High | $39.00 | $9.42 |
| Indicator | BSRR | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 59.34 | 44.61 |
| Support Level | $36.00 | N/A |
| Resistance Level | N/A | $8.13 |
| Average True Range (ATR) | 0.78 | 0.30 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 85.20 | 52.03 |
Sierra Bancorp is a California-based bank holding company, which offers a range of retail and commercial banking services. it offers a wide range of deposit products and services for individuals and businesses including checking accounts, savings accounts, money market demand accounts, time deposits, retirement accounts, and sweep accounts. The company's lending activities cover real estate, commercial (including small business), mortgage warehouse, agricultural and consumer loans, and also offers commercial construction loans and multifamily and agricultural credit facilities among other types of real estate loans.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.